Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.

You may also be interested in...



Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access

Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.

AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme

Exclusive license adds to AMAG's cash reserves and further validates the anemia drug's safety profile

AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme

Exclusive license adds to AMAG's cash reserves and further validates the anemia drug's safety profile

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel